Terms: = Liver cancer AND XPO1, DKFZp686B1823, 7514, ENSG00000082898, O14980, CRM1
33 results:
1. Nuclear to cytoplasmic transport is a druggable dependency in MYC-driven hepatocellular carcinoma.
Deutzmann A; Sullivan DK; Dhanasekaran R; Li W; Chen X; Tong L; Mahauad-Fernandez WD; Bell J; Mosley A; Koehler AN; Li Y; Felsher DW
Nat Commun; 2024 Feb; 15(1):963. PubMed ID: 38302473
[TBL] [Abstract] [Full Text] [Related]
2. Selinexor demonstrates anti-tumor efficacy in paired patient-derived xenograft models and hydrogel-embedded histoculture drug sensitivity test of penile cancer.
He Y; Mei J; Hao H; Liu F; Yi Y; Hu C; Zou F; Lu X
J Cancer Res Clin Oncol; 2023 Aug; 149(10):6931-6941. PubMed ID: 36840755
[TBL] [Abstract] [Full Text] [Related]
3. xpo1 intensifies sorafenib resistance by stabilizing acetylation of NPM1 and enhancing epithelial-mesenchymal transition in hepatocellular carcinoma.
Wang Z; Pan B; Yao Y; Qiu J; Zhang X; Wu X; Tang N
Biomed Pharmacother; 2023 Apr; 160():114402. PubMed ID: 36791564
[TBL] [Abstract] [Full Text] [Related]
4. Primary Soft Tissue Hydatid Cysts.
Patmano M; Çetin DA; Gümüş T; Patmano G; Yenigül AE
Turkiye Parazitol Derg; 2022 May; 46(2):145-149. PubMed ID: 35604194
[TBL] [Abstract] [Full Text] [Related]
5. PSPC1 is a new contextual determinant of aberrant subcellular translocation of oncogenes in tumor progression.
Lang YD; Jou YS
J Biomed Sci; 2021 Aug; 28(1):57. PubMed ID: 34340703
[TBL] [Abstract] [Full Text] [Related]
6. Selinexor decreases HIF-1α via inhibition of crm1 in human osteosarcoma and hepatoma cells associated with an increased radiosensitivity.
von Fallois M; Kosyna FK; Mandl M; Landesman Y; Dunst J; Depping R
J Cancer Res Clin Oncol; 2021 Jul; 147(7):2025-2033. PubMed ID: 33856525
[TBL] [Abstract] [Full Text] [Related]
7. Advanced liver disease outcomes after hepatitis C eradication by human immunodeficiency virus infection in PITER cohort.
Quaranta MG; Ferrigno L; Monti M; Filomia R; Biliotti E; Iannone A; Migliorino G; Coco B; Morisco F; Vinci M; D'Ambrosio R; Chemello L; Massari M; Ieluzzi D; Russo FP; Blanc P; Verucchi G; Puoti M; Rumi MG; Barbaro F; Santantonio TA; Federico A; Chessa L; Gentile I; Zuin M; Parruti G; Morsica G; Kondili LA;
Hepatol Int; 2020 May; 14(3):362-372. PubMed ID: 32279177
[TBL] [Abstract] [Full Text] [Related]
8. Prognostic roles of the transcriptional expression of exportins in hepatocellular carcinoma.
Chen L; Huang Y; Zhou L; Lian Y; Wang J; Chen D; Wei H; Huang M; Huang Y
Biosci Rep; 2019 Aug; 39(8):. PubMed ID: 31371628
[No Abstract] [Full Text] [Related]
9. Antiproliferative activity of (R)-4'-methylklavuzon on hepatocellular carcinoma cells and EpCAM
Delman M; Avcı ST; Akçok İ; Kanbur T; Erdal E; Çağır A
Eur J Med Chem; 2019 Oct; 180():224-237. PubMed ID: 31306909
[TBL] [Abstract] [Full Text] [Related]
10. CRISPR-Cas9 Screening of Kaposi's Sarcoma-Associated Herpesvirus-Transformed Cells Identifies xpo1 as a Vulnerable Target of cancer Cells.
Gruffaz M; Yuan H; Meng W; Liu H; Bae S; Kim JS; Lu C; Huang Y; Gao SJ
mBio; 2019 May; 10(3):. PubMed ID: 31088931
[TBL] [Abstract] [Full Text] [Related]
11. MicroRNA-192-5p is a predictive biomarker of survival for Stage IIIB colon cancer patients.
Li P; Ou Q; Braciak TA; Chen G; Oduncu FS
Jpn J Clin Oncol; 2018 Jul; 48(7):619-624. PubMed ID: 29529220
[TBL] [Abstract] [Full Text] [Related]
12. Thalidomide combined with transcatheter artierial chemoembolzation for primary hepatocellular carcinoma: a systematic review and meta-analysis.
Cao DD; Xu HL; Liu L; Zheng YF; Gao SF; Xu XM; Ge W
Oncotarget; 2017 Jul; 8(27):44976-44993. PubMed ID: 28402958
[TBL] [Abstract] [Full Text] [Related]
13. HIF-2α phosphorylation by CK1δ promotes erythropoietin secretion in liver cancer cells under hypoxia.
Pangou E; Befani C; Mylonis I; Samiotaki M; Panayotou G; Simos G; Liakos P
J Cell Sci; 2016 Nov; 129(22):4213-4226. PubMed ID: 27686097
[TBL] [Abstract] [Full Text] [Related]
14. First-line treatment with FOLFOXIRI for advanced pancreatic cancer in clinical practice: Patients' outcome and analysis of prognostic factors.
Vivaldi C; Caparello C; Musettini G; Pasquini G; Catanese S; Fornaro L; Lencioni M; Falcone A; Vasile E
Int J Cancer; 2016 Aug; 139(4):938-45. PubMed ID: 27038273
[TBL] [Abstract] [Full Text] [Related]
15. Suppressing activity of tributyrin on hepatocarcinogenesis is associated with inhibiting the p53-crm1 interaction and changing the cellular compartmentalization of p53 protein.
Ortega JF; de Conti A; Tryndyak V; Furtado KS; Heidor R; Horst MA; Fernandes LH; Tavares PE; Pogribna M; Shpyleva S; Beland FA; Pogribny IP; Moreno FS
Oncotarget; 2016 Apr; 7(17):24339-47. PubMed ID: 27013579
[TBL] [Abstract] [Full Text] [Related]
16. Prospective association of liver function biomarkers with development of hepatobiliary cancers.
Stepien M; Fedirko V; Duarte-Salles T; Ferrari P; Freisling H; Trepo E; Trichopoulou A; Bamia C; Weiderpass E; Olsen A; Tjønneland A; Overvad K; Boutron-Ruault MC; Fagherazzi G; Racine A; Kühn T; Kaaks R; Aleksandrova K; Boeing H; Lagiou P; Benetou V; Trichopoulos D; Palli D; Grioni S; Tumino R; Naccarati A; Panico S; Bueno-de-Mesquita HB; Peeters PH; Lund E; Quirós JR; Nápoles OC; Sánchez MJ; Dorronsoro M; Huerta JM; Ardanaz E; Ohlsson B; Sjöberg K; Werner M; Nystrom H; Khaw KT; Key TJ; Gunter M; Cross A; Riboli E; Romieu I; Jenab M
Cancer Epidemiol; 2016 Feb; 40():179-87. PubMed ID: 26773278
[TBL] [Abstract] [Full Text] [Related]
17. Oncogenic role of p21 in hepatocarcinogenesis suggests a new treatment strategy.
Ohkoshi S; Yano M; Matsuda Y
World J Gastroenterol; 2015 Nov; 21(42):12150-6. PubMed ID: 26576099
[TBL] [Abstract] [Full Text] [Related]
18. HBx interacted with Smad4 to deprive activin a growth inhibition function in hepatocyte HL7702 on crm1 manner.
Shi Y; Zhang H; Han Z; Mi X; Zhang W; Lv M
Tumour Biol; 2016 Mar; 37(3):3405-15. PubMed ID: 26449823
[TBL] [Abstract] [Full Text] [Related]
19. KPT-330 inhibitor of xpo1-mediated nuclear export has anti-proliferative activity in hepatocellular carcinoma.
Zheng Y; Gery S; Sun H; Shacham S; Kauffman M; Koeffler HP
Cancer Chemother Pharmacol; 2014 Sep; 74(3):487-95. PubMed ID: 25030088
[TBL] [Abstract] [Full Text] [Related]
20. Targeting the nuclear transport machinery by rational drug design.
Mao L; Yang Y
Curr Pharm Des; 2013; 19(12):2318-25. PubMed ID: 23082981
[TBL] [Abstract] [Full Text] [Related]
[Next]
